uric acid and Adrenal Cancer studies

Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.

Research Excerpts

Excerpt	Relevance	Reference
"This study was conducted to elucidate renal uric acid metabolism in patients with primary aldosteronism (PA;16 cases) as compared with normotensive subjects (NT;25 cases) and essential hypertensives (EHT;51 cases)."	7.68	[Study on uric acid metabolism in patients with primary aldosteronism]. ( Iimura, O; Kikuchi, K; Komura, H; Marusaki, S; Namba, M; Ohtomo, T; Satoh, N; Suzuki, S; Takada, T, 1992)
"This study was conducted to elucidate renal uric acid metabolism in patients with primary aldosteronism (PA;16 cases) as compared with normotensive subjects (NT;25 cases) and essential hypertensives (EHT;51 cases)."	3.68	[Study on uric acid metabolism in patients with primary aldosteronism]. ( Iimura, O; Kikuchi, K; Komura, H; Marusaki, S; Namba, M; Ohtomo, T; Satoh, N; Suzuki, S; Takada, T, 1992)
"A pheochromocytoma was found to be the cause of malignant hypertension, which had been present for many years."	1.26	[Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)]. ( Goebel, FD; Gröbner, W; Ohlschlägel, G; Zöllner, N, 1978)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

A1C Level

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (50.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Garrapa, GG	1
Pantanetti, P	1
Arnaldi, G	1
Mantero, F	1
Faloia, E	1
Zöllner, N	1
Goebel, FD	1
Ohlschlägel, G	1
Gröbner, W	1
Namba, M	1
Kikuchi, K	1
Komura, H	1
Suzuki, S	1
Satoh, N	1
Ohtomo, T	1
Takada, T	1
Marusaki, S	1
Iimura, O	1
Crane, MG	1
Harris, JJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism[NCT01990560]	Phase 4	8 participants (Actual)	Interventional	2013-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in hyperglycemia assessed by HbA1c, also known as glycated hemoglobin (NCT01990560)
Timeframe: Baseline, 3 months, and 6 months

Body Mass Index (BMI)

Intervention	percentage of red blood cells (Mean)
	Baseline	3 months	6 months
Mifepristone	6.2	6.1375	6.125

Change in metabolic syndrome as assessed by BMI (NCT01990560)
Timeframe: Baseline and 6 months

CushingQoL

Intervention	kg/m2 (Mean)
	Baseline	6 months
Mifepristone	35.1538	34.5463

Change in Quality of Life - as assessed by the Cushing's Quality of Life questionnaire (CushingQoL). Patient completed questionnaire, 12 items, each scored on a 5 point score, resulting in a score of 12 (worst) to 60 (best) where higher scores indicate more favorable QOL. (NCT01990560)
Timeframe: Baseline and 6 months

Fasting Lipid Profile

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	37.2857	38.7857

Change in metabolic syndrome as assessed by fasting lipid profile which includes Low-density lipoproteins ( LDL), High-density lipoproteins (HDL), and Triglycerides (Trigs) levels, and total cholesterol which is the sum of HDL plus LDL and 20% of trigs. (NCT01990560)
Timeframe: Baseline and 6 months

HOMA-IR

Intervention	mg/dL (Mean)
	Total Cholesterol Baseline	Total Cholesterol 6 months	LDL baseline	LDL 6 months	HDL Baseline	HDL 6 months	Trigs Baseline	Trigs 6 months
Mifepristone	178.63	171.43	97.88	104.37	59.13	46.86	107.88	100.29

Change in hyperglycemia assessed by Homeostatic Model Assessment of Insulin Resistance, HOMA-IR (a validated assessment of insulin resistance). HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. (NCT01990560)
Timeframe: Baseline and 6 months

Hospital Anxiety and Depression Scale (HADS)

Intervention	HOMA-IR score (Mean)
	Baseline	6 months
Mifepristone	2.418	1.465

Change in Quality of Life as assessed by the Hospital Anxiety and Depression Scale (HADS). Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression (NCT01990560)
Timeframe: Baseline and 6 months

Nottingham Health Profile (NHP)

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	16.2857	11.1667

Change in Quality of Life as assessed by the Nottingham Health Profile (NHP) which is a patient reported questionnaire to measure a patient's view of their own health status. There are 6 sections (Energy level, Pain, Emotional Reaction, Sleep, Social Isolation, and Physical Abilities. All questions have only yes/no answer options and each section score is weighted so that the possible score range for any section is 0-100. The higher the score, the greater the number and severity of problems. (NCT01990560)
Timeframe: Baseline and 6 months

Quality of Life

Intervention	units on a scale (Mean)
	Energy Level (EL) Baseline	EL 6 months	Pain (P) Baseline	P 6 months	Emotional Reaction (ER) Baseline	ER 6 months	Sleep (S) Baseline	S 6 months	Social Isolation (SI) Baseline	SI 6 months	Physical Abilities (PA) Baseline	PA 6 months
Mifepristone	32.60	45.40	24.88	32.08	27.03	35.09	24.87	31.15	20.09	31.15	23.06	27.49

Change in Quality of Life as assessed by the Beck Depression Inventory. a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms. (NCT01990560)
Timeframe: Baseline and 6 months

State Trait Anxiety Inventory (STAI)

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	16.1429	11.7143

Change in Quality of Life - as assessed by the State Trait Anxiety Inventory (STAI). The State-Trait Anxiety Inventory both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored and averaged. Total scores range from 20 to 80, with higher scores correlating with greater anxiety. (NCT01990560)
Timeframe: Baseline and 6 months

Waist Circumference

Intervention	units on a scale (Mean)
	Baseline	6 months
Mifepristone	25.4286	28.8571

Change in metabolic syndrome as assessed by waist circumference (NCT01990560)
Timeframe: Baseline and 6 months

Weight

Intervention	cm (Mean)
	Baseline	6 months
Mifepristone	103.25	99.3125

Change in metabolic syndrome as assessed by weight (NCT01990560)
Timeframe: Baseline and 6 months

Article	Year
[Juvenile gout with decreased activity of hypoxanthine-guanine-phosphoribosyl transferase and pheochromocytoma: partial persistence of tophi despite uric-acid reducing treatment for 12 years (author's transl)]. Deutsche medizinische Wochenschrift (1946), 1978, Jun-23, Volume: 103, Issue:25 Topics: Adrenal Gland Neoplasms; Allopurinol; Gout; Humans; Hypertension, Malignant; Hypoxanthine Phosphorib	1978
[Study on uric acid metabolism in patients with primary aldosteronism]. Nihon Naibunpi Gakkai zasshi, 1992, Jan-20, Volume: 68, Issue:1 Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aldosterone; Female; Humans; Hyperaldosteron	1992
Effect of spironolactone in hypertensive patients. The American journal of the medical sciences, 1970, Volume: 260, Issue:6 Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antihypertensive Agents; Blood Urea Nitrogen; Fema	1970

uric acid and Adrenal Cancer